Literature DB >> 16129024

Factor XIII (FXIII) and angiogenesis.

R Dardik1, J Loscalzo, A Inbal.   

Abstract

Factor XIII is a plasma transglutaminase that participates in the final stage of the coagulation cascade. Thrombin-activated FXIII (FXIIIa) catalyzes the formation of covalent cross-links between gamma-glutamyl and epsilon-lysyl residues on adjacent fibrin chains in polymerized fibrin to yield the mature clot. In addition to its role in hemostasis, FXIII is known to participate in wound healing and embryo implantation, which are processes involving angiogenesis. In this review, we discuss the role of FXIII in angiogenesis and the molecular mechanisms underlying its proangiogenic effects. The FXIII role in tissue repair and remodeling may at least in part be attributed to its pro-angiogenic activity.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16129024     DOI： 10.1111/j.1538-7836.2005.01473.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


  24 in total

1.  Vena cava and aortic smooth muscle cells express transglutaminases 1 and 4 in addition to transglutaminase 2.

Authors:  Kyle B Johnson; Humphrey Petersen-Jones; Janice M Thompson; Kiyotaka Hitomi; Miho Itoh; Erik N T P Bakker; Gail V W Johnson; Gozde Colak; Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

Review 2.  Roles of transglutaminases in cardiac and vascular diseases.

Authors:  David C Sane; Jimmy L Kontos; Charles S Greenberg
Journal:  Front Biosci       Date:  2007-01-01

3.  Overexpression of Notch1 ectodomain in myeloid cells induces vascular malformations through a paracrine pathway.

Authors:  Xiujie Li; Ezequiel Calvo; Marc Cool; Pavel Chrobak; Denis G Kay; Paul Jolicoeur
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 4.  Remodeling and Repair in Rhinosinusitis.

Authors:  Jean-Baptiste Watelet; Jean-Michel Dogne; François Mullier
Journal:  Curr Allergy Asthma Rep       Date:  2015-06       Impact factor: 4.806

Review 5.  Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism.

Authors:  Rami A Al-Horani; Srabani Kar
Journal:  Eur J Med Chem       Date:  2020-05-18       Impact factor: 6.514

Review 6.  Genetic predictors of response to photodynamictherapy.

Authors:  Francesco Parmeggiani; Donato Gemmati; Ciro Costagliola; Francesco Semeraro; Paolo Perri; Sergio D'Angelo; Mario R Romano; Katia De Nadai; Adolfo Sebastiani; Carlo Incorvaia
Journal:  Mol Diagn Ther       Date:  2011-08-01       Impact factor: 4.074

7.  Efficacy of administration of coagulation factor XIII with definitive surgery for multiple intractable enterocutaneous fistulae in a patient with decreased factor XIII activity.

Authors:  Susumu Saigusa; Takeshi Yamamura; Koji Tanaka; Masaki Ohi; Aya Kawamoto; Minako Kobayashi; Yasuhiro Inoue; Masato Kusunoki
Journal:  BMJ Case Rep       Date:  2011-03-15

Review 8.  State of the art in factor XIII laboratory assessment.

Authors:  Michael A Durda; Alisa S Wolberg; Bryce A Kerlin
Journal:  Transfus Apher Sci       Date:  2018-08-04       Impact factor: 1.764

9.  Factor XIIIA-V34L and factor XIIIB-H95R gene variants: effects on survival in myocardial infarction patients.

Authors:  Donato Gemmati; Federica Federici; Gianluca Campo; Silvia Tognazzo; Maria L Serino; Monica De Mattei; Marco Valgimigli; Patrizia Malagutti; Gabriele Guardigli; Paolo Ferraresi; Francesco Bernardi; Roberto Ferrari; Gian L Scapoli; Linda Catozzi
Journal:  Mol Med       Date:  2007 Jan-Feb       Impact factor: 6.354

10.  Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel.

Authors:  Rolf P Kreutz; Janelle Owens; Deshun Lu; Perry Nystrom; Yan Jin; Yvonne Kreutz; Zeruesenay Desta; David A Flockhart
Journal:  Platelets       Date:  2014-05-15       Impact factor: 3.862
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.